• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Catalyst Pharmaceuticals Inc.

    4/9/25 8:55:12 AM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CPRX alert in real time by email
    8-K
    NASDAQ false 0001369568 0001369568 2025-04-08 2025-04-08

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934

    Date of Report (Date of Earliest Event Reported): April 8, 2025

     

     

    CATALYST PHARMACEUTICALS, INC.

    (Exact Name Of Registrant As Specified In Its Charter)

     

     

     

    Delaware   001-33057   76-0837053
    (State or other jurisdiction
    of incorporation)
     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    355 Alhambra Circle  
    Suite 801  
    Coral Gables, Florida   33134
    (Address of principal executive offices)   (Zip Code)

    Registrant’s telephone number, including area code: (305) 420-3200

    Not Applicable

    Former Name or Former address, if changed since last report

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Each Class

     

    Name of Exchange

    on Which Registered

     

    Ticker

    Symbol

    Common Stock, par value $0.001 per share   NASDAQ Capital Market   CPRX

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging Growth Company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Item 8.01

    Other Events

    On April 8, 2025, the Company issued a press release reporting that its sub-licensee in Canada, Kye Pharmaceuticals, Inc., has announced that Health Canada has accepted the New Drug Submission for AGAMREE®, a novel corticosteroid treatment for Duchenne Muscular Dystrophy (DMD), for review. The submission has been granted Priority Review, expediting the regulatory process with the potential for marketing authorization before the end of 2025. If approved, AGAMREE® would be the first and only treatment option indicated for patients diagnosed with DMD in Canada.

    A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

     

    Item 9.01

    Financial Statements and Exhibits.

     

      (d)

    Exhibits

     

    99.1    Press release issued by the Company on April 8, 2025.
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

    2


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Catalyst Pharmaceuticals, Inc.
    By:  

    /s/ Michael W. Kalb

      Michael W. Kalb
      Executive Vice President and Chief Financial Officer

    Dated: April 9, 2025

     

    3

    Get the next $CPRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CPRX

    DatePrice TargetRatingAnalyst
    2/4/2025$28.00Outperform
    Robert W. Baird
    11/18/2024$35.00Overweight
    Stephens
    3/14/2024$27.00Buy
    Citigroup
    3/7/2024$23.00Buy
    BofA Securities
    12/21/2023$30.00Outperform
    Oppenheimer
    8/24/2022$10.00 → $15.50Buy → Neutral
    ROTH Capital
    2/8/2022$9.00 → $12.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CPRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Robert W. Baird initiated coverage on Catalyst Pharma with a new price target

      Robert W. Baird initiated coverage of Catalyst Pharma with a rating of Outperform and set a new price target of $28.00

      2/4/25 7:01:07 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stephens initiated coverage on Catalyst Pharma with a new price target

      Stephens initiated coverage of Catalyst Pharma with a rating of Overweight and set a new price target of $35.00

      11/18/24 8:40:25 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citigroup initiated coverage on Catalyst Pharma with a new price target

      Citigroup initiated coverage of Catalyst Pharma with a rating of Buy and set a new price target of $27.00

      3/14/24 7:36:28 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CPRX
    SEC Filings

    See more
    • SEC Form 144 filed by Catalyst Pharmaceuticals Inc.

      144 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)

      6/6/25 3:42:11 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Catalyst Pharmaceuticals Inc.

      8-K - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)

      6/2/25 4:35:55 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Catalyst Pharmaceuticals Inc.

      144 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)

      5/30/25 4:04:22 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care